# ANNEXE 10 – Caractéristiques des patients selon les mortalités intra-USI et mortalités à J28, à M6 et M12

Dans le tableau se trouve les différentes caractéristiques de nos patients en fonction de la mortalité intra-USI, de la mortalité à J28, à M6 et à M12. Dans la deuxième colonne, on trouve le nombre de patient exprimant cette variable dans la population initiale et le pourcentage par rapport à celle-ci entre parenthèses. Pour les colonnes suivantes, les pourcentages entre parenthèse se rapportent au nombre de patient décédés parmi le nombre de patient exprimant cette variable dans la population initiale. Les variables quantitatives sont soit exprimé en médiane [quartiles] ou moyenne ± écart-type.

<table><thead><tr><th>Caractéristiques des patients</th><th>Nombre de patient total n = 101*</th><th>Décédés intra-USI n = 32</th><th>Décédés à J28 n = 32</th><th>Décédés à M6 n = 61</th><th>Décédés à M12 n = 75</th></tr></thead><tbody><tr><td><strong>GENERALITES</strong></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Sexe féminin</td><td>26 (25,7)</td><td>6 (23,3)</td><td>7 (26,9)</td><td>11 (42,3)</td><td>17 (65,4)</td></tr><tr><td>Tabagisme (actif ou sevré)</td><td>90 (89,1)</td><td>29 (32,2)</td><td>37 (41,1)</td><td>56 (62,2)</td><td>69 (76,7)</td></tr><tr><td>Perfomans statut (n=100)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>• 0-1</td><td>50 (50)</td><td>12 (24)</td><td>15 (30)</td><td>24 (48)</td><td>33 (66)</td></tr><tr><td>• 2-3</td><td>50 (50)</td><td>19 (38)</td><td>24 (48)</td><td>36 (72)</td><td>41 (82)</td></tr><tr><td>Statut réanimatoire</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>• 2</td><td>18 (17,8)</td><td>7 (38,9)</td><td>11 (61,1)</td><td>16 (88,9)</td><td>18 (100)</td></tr><tr><td>• 3</td><td>56 (55,4)</td><td>19 (33,9)</td><td>20 (35,7)</td><td>28 (50)</td><td>35 (62,5)</td></tr><tr><td>• Non renseigné</td><td>27 (26,7)</td><td>6 (22,2)</td><td>9 (33,3)</td><td>17 (63)</td><td>22 (81,5)</td></tr><tr><td><strong>COMORBIDITES</strong></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Pathologie respiratoire sévère</td><td>26 (25,7)</td><td>8 (30,8)</td><td>9 (34,6)</td><td>14 (53,8)</td><td>17 (65,4)</td></tr><tr><td>• OLD</td><td>10 (38,5)</td><td>4 (40)</td><td>5 (50)</td><td>6 (60)</td><td>9 (90)</td></tr><tr><td>• VNI</td><td>6 (23,1)</td><td>3 (50)</td><td>3 (50)</td><td>3 (50)</td><td>4 (66,7)</td></tr><tr><td>VEMS (en %) (n = 61)</td><td>66,6 ± 21</td><td>66,5 ± 16,5</td><td>66,9 ± 16,2</td><td>64,8 ± 16,1</td><td>66 ± 16,6</td></tr><tr><td>Insuffisance cardiaque chronique</td><td>36 (35,6)</td><td>10 (27,8)</td><td>12 (33,3)</td><td>23 (63,9)</td><td>26 (72,2)</td></tr><tr><td>Insuffisance rénale chronique</td><td>17 (16,8)</td><td>7 (41,1)</td><td>8 (47,1)</td><td>13 (76,5)</td><td>14 (82,4)</td></tr><tr><td>Antécédent d'AVC</td><td>5 (5)</td><td>2 (40)</td><td>2 (40)</td><td>3 (60)</td><td>4 (80)</td></tr><tr><td>Diabète</td><td>27 (26,7)</td><td>6 (22,2)</td><td>8 (26,6)</td><td>14 (51,9)</td><td>20 (74,1)</td></tr><tr><td>Lymphopénie chronique</td><td>33 (32,7)</td><td>10 (30,3)</td><td>12 (36,4)</td><td>20 (60,6)</td><td>27 (81,8)</td></tr><tr><td>Autre néoplasie</td><td>19 (18,8)</td><td>5 (26,3)</td><td>6 (31,6)</td><td>9 (47,')</td><td>14 (7347)</td></tr><tr><td>Score de Charlson modifié</td><td>2,3 ± 2,2</td><td>2,1 ± 2,1</td><td>2,1 ± 2,2</td><td>2,4 ± 2,2</td><td>2,4 ± 2,2</td></tr><tr><td>Albumine ≤ 25 g/l (n = 98)</td><td>17 (16,8)</td><td>7 (41,2)</td><td>11(64,7)</td><td>14 (82,2)</td><td>15 (88,2)</td></tr><tr><td><strong>ANATOMOPATHOLOGIE</strong></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Epidermoïde</td><td>24 (23,8)</td><td>9 (37,5)</td><td>9 (37,5)</td><td>16 (66,7)</td><td>17 (70,8)</td></tr><tr><td>Adénocarcinome</td><td>64 (63,4)</td><td>21 (32,8)</td><td>28 (43,8)</td><td>41 (60,4)</td><td>51 (79,7)</td></tr><tr><td>Autre histologie (CBNPC)</td><td>13 (12,9)</td><td>2 (15,4)</td><td>3 (23,1)</td><td>4 (30,8)</td><td>7 (53,8)</td></tr><tr><td>PD-L1 négatif</td><td>27 (27,5)</td><td>9 (33,3)</td><td>12 (44,4)</td><td>21 (77,8)</td><td>24 (88,9)</td></tr><tr><td>PD-L1 entre 1 et 49 %</td><td>36 (36,7)</td><td>12 (33,3)</td><td>15 (41,7)</td><td>21 (58,3)</td><td>27 (75)</td></tr><tr><td>PD-L1 ≥ 50 %</td><td>35 (35,7)</td><td>10 (28,6)</td><td>12 (34,3)</td><td>18 (51,4)</td><td>23 (65,7)</td></tr><tr><td>Pas d'altération moléculaire</td><td>35 (34,7)</td><td>15 (42,9)</td><td>16 (45,7)</td><td>24 (68,6)</td><td>26 (74,3)</td></tr></tbody></table>
<table><tr><td>Altération ciblable par un TKI</td><td>29 (28,7)</td><td>8 (27,9)</td><td>9 (31)</td><td>13 (44,8)</td><td>19 (65,5)</td></tr><tr><td>Altération non ciblable par un TKI</td><td>37 (36,6)</td><td>9 (24,3)</td><td>15 (40,5)</td><td>24 (64,9)</td><td>30 (81,1)</td></tr><tr><td>EGFR (ciblable) (n = 73)</td><td>8 (11)</td><td>0 (0)</td><td>1 (12,5)</td><td>3 (37,5)</td><td>5 (62,5)</td></tr><tr><td>ALK (n = 76)</td><td>4 (5,3)</td><td>1 (25)</td><td>1 (25)</td><td>1 (25)</td><td>2 (50)</td></tr><tr><td>KRAS (n = 73)</td><td>25 (34,2)</td><td>9 (36)</td><td>11 (44)</td><td>13 (52)</td><td>18 (72)</td></tr><tr><td>dont KRAS G12C (n = 25)</td><td>15 (60)</td><td>6 (40)</td><td>6 (40)</td><td>7 (50)</td><td>11 (73,3)</td></tr><tr><td>ROS-1 (n = 73)</td><td>3 (4,1)</td><td>0 (0)</td><td>1 (33,3)</td><td>2 (66,7)</td><td>2 (66,7)</td></tr><tr><td>SMARC4 (n = 68)</td><td>5 (7,4)</td><td>1 (20)</td><td>1 (20)</td><td>1 (20)</td><td>4 (80)</td></tr><tr><td>BRAF V600E (n = 69)</td><td>2 (1,4)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td></tr><tr><td>TP-53 (n = 68)</td><td>32 (47,1)</td><td>8 (25)</td><td>12 (37,5)</td><td>22 (68,8)</td><td>24 (75)</td></tr><tr><td>HER-2 (n = 67)</td><td>1 (1,5)</td><td>1 (100)</td><td>1 (100)</td><td>1 (100)</td><td>1 (100)</td></tr><tr><td>STK-11 et KEAP-1 (n = 67)</td><td>10 (14,9)</td><td>0 (0)</td><td>1 (10)</td><td>4 (40)</td><td>8 (80)</td></tr><tr><td>Sans significativité clinique (n = 67)</td><td>19 (28,4)</td><td>5 (26,3)</td><td>6 (31,6)</td><td>10 (52,6)</td><td>14 (73,7)</td></tr></table>

## STADES ET LOCALISATIONS

<table><tr><td>Stade III</td><td>20 (19,8)</td><td>5 (23,8)</td><td>5 (23,8)</td><td>7 (38,1)</td><td>13 (61,9)</td></tr><tr><td>Stade IV</td><td>81 (80,1)</td><td>27 (33,3)</td><td>35 (43,8)</td><td>53 (66,3)</td><td>62 (77,5)</td></tr><tr><td>Dont oligométastique</td><td>15 (18,5)</td><td>2 (13,3)</td><td>2 (13,3)</td><td>3 (20)</td><td>5 (33,3)</td></tr><tr><td>Stade III + oligométastatique</td><td>35 (34,7)</td><td>6 (17,1)</td><td>6 (17,1)</td><td>10 (28,6)</td><td>17 (48,6)</td></tr><tr><td>Métastase cérébrale</td><td>35 (43,2)</td><td>13 (46,4)</td><td>18 (50)</td><td>26 (74,3)</td><td>29 (46)</td></tr><tr><td>Métastase ganglionnaire</td><td>38 (46,9)</td><td>15 (39,5)</td><td>20 (52,6)</td><td>27 (71,1)</td><td>32 (84,2)</td></tr><tr><td>Métastase osseuse</td><td>29 (35,8)</td><td>12 (41,4)</td><td>16 (55,2)</td><td>23 (79,3)</td><td>26 (89,7)</td></tr><tr><td>Métastase pulmonaire</td><td>45 (55,6)</td><td>17 (37,8)</td><td>22 (48,9)</td><td>31 (68,9)</td><td>35 (77,8)</td></tr><tr><td>Métastase séreuse</td><td>23 (28,4)</td><td>9 (39,1)</td><td>14 (60,9)</td><td>18 (78,3)</td><td>22 (95,7)</td></tr><tr><td>Métastase surrénale</td><td>20 (24,7)</td><td>8 (40)</td><td>10 (50)</td><td>12 (60)</td><td>15 (75)</td></tr><tr><td>Métastase hépatique</td><td>14 (17,3)</td><td>4 (28,6)</td><td>7 (50)</td><td>10 (71,4)</td><td>10 (71,4)</td></tr><tr><td>Envahissement gros vaisseaux</td><td>36 (35,6)</td><td>11 (30,6)</td><td>15 (41,7)</td><td>24 (66,7)</td><td>29 (80,6)</td></tr></table>

## PATHOLOGIE ONCOLOGIQUE

<table><tr><td>Antécédent de traitement local</td><td>60 (59,4)</td><td>18 (30)</td><td>20 (33,3)</td><td>33 (55)</td><td>41 (68,3)</td></tr><tr><td>• Chirurgie</td><td>9 (8,9)</td><td>1 (11,1)</td><td>3 (33,3)</td><td>3 (33,3)</td><td>4 (44,4)</td></tr><tr><td>• ARC</td><td>28 (27,7)</td><td>12 (42,9)</td><td>12 (42,9)</td><td>18 (64,3)</td><td>23 (82,1)</td></tr><tr><td>• RT stéréotaxique</td><td>23 (22,8)</td><td>5 (21,7)</td><td>5 (21,7)</td><td>12 (52,2)</td><td>14 (60,9)</td></tr><tr><td>Radiothérapie antalgique (n=100)</td><td>16 (16)</td><td>5 (31,3)</td><td>8 (50)</td><td>13 (81,3)</td><td>16 (100)</td></tr><tr><td>Nombre de ligne de traitement</td><td>1,5 ± 0,9</td><td>1,7 ± 1,1</td><td>0,6 ± 0,8</td><td>0,6 ± 0,8</td><td>0,7 ± 0,8</td></tr></table>

### Traitement actuel

<table><tr><td>CT seule</td><td>34 (33,7)</td><td>12 (37,5)</td><td>14 (41,2)</td><td>22 (64,7)</td><td>26 (76,5)</td></tr><tr><td>CT-ICI</td><td>14 (13,9)</td><td>4 (28,6)</td><td>6 (42,9)</td><td>9 (64,3)</td><td>11 (78,6)</td></tr><tr><td>ICI seul</td><td>18 (17,8)</td><td>7 (38,9)</td><td>7 (38,9)</td><td>11 (61,1)</td><td>13 (72,2)</td></tr><tr><td>TKI</td><td>14 (13,9)</td><td>2 (14,2)</td><td>3 (21,4)</td><td>8 (57,1)</td><td>11 (78,6)</td></tr><tr><td>Non traité</td><td>21 (20,8)</td><td>7 (33,3)</td><td>10 (47,6)</td><td>11 (52,4)</td><td>14 (66,7)</td></tr></table>

## STATUT FONCTIONNEL

<table><tr><td>Phase diagnostic</td><td>32 (31,7)</td><td>10 (31,3)</td><td>15 (46,9)</td><td>19 (59,4)</td><td>24 (75)</td></tr><tr><td>Réponse</td><td>16 (15,8)</td><td>5 (31,3)</td><td>5 (31,3)</td><td>8 (50)</td><td>11 (68,8)</td></tr><tr><td>Stabilité</td><td>25 (25)</td><td>8 (32)</td><td>7 (28)</td><td>13 (52)</td><td>16 (64)</td></tr><tr><td>Progression</td><td>27 (26,7)</td><td>9 (33,3)</td><td>13 (48,1)</td><td>20 (74,1)</td><td>23 (85,2)</td></tr><tr><td>Phase palliative</td><td>1 (1)</td><td>0 (0)</td><td>0 (0)</td><td>1 (100)</td><td>1 (100)</td></tr></table>

## ADMISSION
<table><tbody><tr><td>Admission en réanimation</td><td>31 (30,7)</td><td>14 (45,2)</td><td>14 (45,2)</td><td>18 (58,1)</td><td>21 (67,7)</td></tr><tr><td>Durée de séjour total</td><td>8 ± 7,8</td><td>6,3 ± 5,6</td><td>6,8 ± 5,4</td><td>6,8 ± 5,2</td><td>8 ± 7,9</td></tr><tr><td>Lieu d'admission</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Urgences</td><td>51 (50,5)</td><td>14 (27,5)</td><td>17 (33,3)</td><td>27 (52,9)</td><td>36 (70,6)</td></tr><tr><td>Intra-hospitalier</td><td>50 (49,5)</td><td>18 (36)</td><td>23 (46)</td><td>34 (68)</td><td>39 (78)</td></tr><tr><td>Cause rapidement réversible</td><td>43 (42,6)</td><td>10 (23,3)</td><td>11 (25,6)</td><td>21 (48,8)</td><td>29 (67,4)</td></tr><tr><td>En fonction du cancer</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Non lié au cancer</td><td>32 (31,7)</td><td>10 (31,3)</td><td>9 (28,1)</td><td>21 (65,6)</td><td>24 (75)</td></tr><tr><td>Lié à la prise en charge du cancer</td><td>38 (37,6)</td><td>13 (34,2)</td><td>16 (42,1)</td><td>19 (50)</td><td>28 (73,7)</td></tr><tr><td>Lié à la progression</td><td>24 (23,8)</td><td>7 (29,1)</td><td>13 (54,2)</td><td>18 (75)</td><td>20 (83,3)</td></tr><tr><td>Evènement induit par le cancer</td><td>14 (13,9)</td><td>4 (28,6)</td><td>8 (57,1)</td><td>9 (64,3)</td><td>9 (64,3)</td></tr><tr><td>En fonction de la défaillance d'organe</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Respiratoire</td><td>71 (70,3)</td><td>23 (32,4)</td><td>32 (45,1)</td><td>44 (62)</td><td>53 (74,6)</td></tr><tr><td>• Obstruction des VA</td><td>5 (7)</td><td>2 (40)</td><td>2 (40)</td><td>3 (60)</td><td>5 (80)</td></tr><tr><td>• Hémoptysie</td><td>7 (9,9)</td><td>1 (14,3)</td><td>2 (28,6)</td><td>4 (57,1)</td><td>4 (57,1)</td></tr><tr><td>• Atteinte pleurale</td><td>15 (21,1)</td><td>4 (26,7)</td><td>8 (53,3)</td><td>11 (73,3)</td><td>12 (80)</td></tr><tr><td>• Hypoxémie</td><td>59 (83,1)</td><td>21 (35,5)</td><td>29 (49,2)</td><td>39 (66,1)</td><td>47 (79,7)</td></tr><tr><td>• Acidose hypercapnique</td><td>19 (26,8)</td><td>8 (42,1)</td><td>10 (52,6)</td><td>13 (68,4)</td><td>15 (78,9)</td></tr><tr><td>Cardiaque</td><td>51 (50,5)</td><td>20 (39,2)</td><td>24 (47,1)</td><td>35 (68,6)</td><td>42 (82,4)</td></tr><tr><td>• Arrêt cardio-respiratoire</td><td>8 (15,7)</td><td>4 (50)</td><td>5 (62,5)</td><td>5 (62,5)</td><td>7 (87,5)</td></tr><tr><td>• Ischémie</td><td>10 (19,6)</td><td>5 (50)</td><td>4 (40)</td><td>8 (80)</td><td>8 (80)</td></tr><tr><td>• Myo-péricardique</td><td>9 (17,6)</td><td>4 (44,4)</td><td>5 (55,6)</td><td>6 (66,7)</td><td>7 (77,8)</td></tr><tr><td>• Décompensation cardiaque gauche (hors ischémie)</td><td>20 (39,2)</td><td>8 (40)</td><td>8 (40)</td><td>13 (65)</td><td>16 (80)</td></tr><tr><td>• Hypertension pulmonaire</td><td>11 (21,6)</td><td>5 (45,5)</td><td>7 (63,6)</td><td>8 (72,7)</td><td>9 (81,8)</td></tr><tr><td>• Atteinte thrombotique</td><td>6 (11,8)</td><td>2 (33,3)</td><td>4 (66,7)</td><td>5 (83,3)</td><td>5 (83,3)</td></tr><tr><td>Infectieux</td><td>54 (53,5)</td><td>19 (35,2)</td><td>27 (50)</td><td>33 (61,1)</td><td>38 (70,4)</td></tr><tr><td>• Pulmonaire</td><td>41 (75,9)</td><td>14 (34,1)</td><td>20 (48,8)</td><td>25 (61)</td><td>29 (70,7)</td></tr><tr><td>• Urinaire</td><td>3 (5,6)</td><td>2 (66,7)</td><td>2 (66,7)</td><td>2 (66,7)</td><td>2 (66,7)</td></tr><tr><td>• Digestif</td><td>5 (9,3)</td><td>2 (40)</td><td>2 (40)</td><td>3 (60)</td><td>3 (60)</td></tr><tr><td>• Endocardite</td><td>1 (1,9)</td><td>1 (100)</td><td>1 (100)</td><td>1 (100)</td><td>1 (100)</td></tr><tr><td>• Accès veineux</td><td>5 (9,3)</td><td>2 (40)</td><td>2 (40)</td><td>2 (40)</td><td>3 (60)</td></tr><tr><td>Hématologique</td><td>14 (13,9)</td><td>8 (57,1)</td><td>10 (71,4)</td><td>13 (92,9)</td><td>13 (92,9)</td></tr><tr><td>Neurologique</td><td>15 (14,9)</td><td>9 (60)</td><td>9 (60)</td><td>12 (80)</td><td>13 (86,7)</td></tr><tr><td>Néphrologique</td><td>25 (24,8)</td><td>13 (52)</td><td>14 (56)</td><td>18 (72)</td><td>21 (84)</td></tr><tr><td>Digestif</td><td>12 (11,9)</td><td>2 (8,3)</td><td>3 (25)</td><td>8 (66,7)</td><td>9 (75)</td></tr><tr><td>Hépatique</td><td>9 (8,9)</td><td>6 (66,7)</td><td>6 (66,7)</td><td>9 (100)</td><td>9 (100)</td></tr><tr><td>Intervention en urgence</td><td>20 (19,8)</td><td>7 (35)</td><td>6 (30)</td><td>12 (60)</td><td>12 (60)</td></tr><tr><td>Toxicité spécifique suspectée d'une thérapie anti-cancéreuse (n = 100)</td><td>14 (14)</td><td>2 (14,3)</td><td>2 (14,3)</td><td>5 (35,7)</td><td>9 (64,3)</td></tr></tbody></table>
VARIABLES D'ENTREE ET TRAITEMENTS EN REANIMATION

<table><tr><td>IGS II</td><td>46,3 ±<br>23,5</td><td>63,3<br>± 27,3</td><td>59 ± 26,2</td><td>51,5<br>± 26,4</td><td>48 ± 25,2</td></tr><tr><td>APACHE II</td><td>19,6 ± 8,4</td><td>25,5 ± 8,9</td><td>23,5 ± 8,9</td><td>21,4 ± 9,1</td><td>20,1 ± 8,9</td></tr><tr><td>Présence d'un état de choc</td><td>32 (31,7)</td><td>19 (57,6)</td><td>20 (62,5)</td><td>22 (68,8)</td><td>23 (71,9)</td></tr><tr><td>Débit d'oxygène (en l/min)</td><td>11,3<br>± 18,5</td><td>18,2<br>± 24,7</td><td>18,6<br>± 23,5</td><td>14,6 ± 22</td><td>12,4<br>± 19,9</td></tr><tr><td>PaO2/FiO2<br>(si IOT ou VNI ou OHD)</td><td>185 ± 99</td><td>153 ± 82</td><td>148 ± 84</td><td>155 ± 85</td><td>162 ± 89</td></tr><tr><td>Ventilation mécanique</td><td>33 (32,7)</td><td>19 (57,6)</td><td>19 (57,6)</td><td>22 (66,7)</td><td>25 (75,8)</td></tr><tr><td>• VNI</td><td>16 (38,1)</td><td>8 (50)</td><td>8 (50)</td><td>10 (62,5)</td><td>12 (75)</td></tr><tr><td>• IOT</td><td>26 (61,9)</td><td>16 (61,5)</td><td>16 (61,5)</td><td>18 (69,2)</td><td>19 (73,1)</td></tr><tr><td>Oxygène haut débit</td><td>22 (21,8)</td><td>10 (45,4)</td><td>14 (63,6)</td><td>17 (77,3)</td><td>19 (86,4)</td></tr><tr><td>Amines</td><td>32 (31,7)</td><td>18 (56,3)</td><td>19 (59,4)</td><td>22 (68,8)</td><td>23 (71,9)</td></tr><tr><td>NORADRENALINE</td><td>29 (90,6)</td><td>16 (55,1)</td><td>17 (58,6)</td><td>19 (65,5)</td><td>20 (69)</td></tr><tr><td>DOBUTAMINE</td><td>3 (9,4)</td><td>2 (66,6)</td><td>2 (66,7)</td><td>3 (100)</td><td>3 (100)</td></tr><tr><td>Epuration extra-rénale</td><td>7 (6,9)</td><td>4 (57,1)</td><td>4 (57,1)</td><td>6 (85,7)</td><td>6 (85,7)</td></tr><tr><td>Utilisation d'antibiotique</td><td>75 (74,3)</td><td>25 (33,3)</td><td>34 (45,3)</td><td>44 (58,7)</td><td>54 (72)</td></tr><tr><td>Utilisation de corticoïdes</td><td>46 (45,5)</td><td>17 (37)</td><td>22 (47,8)</td><td>29 (63)</td><td>36 (78,3)</td></tr><tr><td>Cure de CT et/ou ICI</td><td>7 (6,9)</td><td>0 (0)</td><td>3 (42,9)</td><td>4 (57,1)</td><td>6 (85,7)</td></tr><tr><td>Utilisation de TKI</td><td>7 (6,9)</td><td>0 (0)</td><td>2 (28,6)</td><td>4 (57,1)</td><td>5 (71,4)</td></tr><tr><td>Geste au bloc opératoire</td><td>24 (23,8)</td><td>6 (25)</td><td>6 (25)</td><td>13 (54,2)</td><td>14 (58,3)</td></tr><tr><td>Bronchoscopie rigide</td><td>2 (2)</td><td>0 (0)</td><td>0 (0)</td><td>0 (0)</td><td>1 (50)</td></tr><tr><td>Bronchoscopie souple</td><td>22 (21,8)</td><td>10 (45,5)</td><td>11 (50)</td><td>14 (63,6)</td><td>16 (72,7)</td></tr><tr><td>LATA</td><td>32 (31,7)</td><td>25 (78,1)</td><td>29 (90,6)</td><td>32 (100)</td><td>32 (100)</td></tr></table>
BIBLIOGRAPHIE

1. Le cancer du poumon - Les cancers les plus fréquents [Internet]. [cité 13 nov 2024]. Disponible sur: https://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Les-cancers-les-plus-frequents/Cancer-du-poumon

2. Catherine Hill, Agnès Laplanche. Évolution de la consommation de cigarettes en France par sexe, 1900-2003. BEH. 2005;(21-22):107-8.

3. Fervers B, Clin B, Pairon JC. Épidémiologie du cancer du poumon en France: Epidemiology of lung cancer in France. Revue des Maladies Respiratoires Actualités. 1 oct 2023;15(2, Supplement 1):2S5-9.

4. Andujar P, Fervers B, Delva F, Clin B, Pairon JC. Épidémiologie du cancer bronchique en France, Belgique et Suisse – Principaux facteurs de risque environnementaux et professionnels. Revue des Maladies Respiratoires Actualités. oct 2024;16(2):2S3-9.

5. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. New England Journal of Medicine. 6 déc 2018;379(23):2220-9.

6. Nicholson AG, Tsao MS, Beasley MB, Borczuk AC, Brambilla E, Cooper WA, et al. The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015. Journal of Thoracic Oncology. 1 mars 2022;17(3):362-87.

7. Couraud PS. Référentiels Auvergne Rhône-Alpes en oncologie thoracique. 2024;

8. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 4 mars 2011;144(5):646-74.

9. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discovery. 12 janv 2022;12(1):31-46.

10. Song Y, Wang Y, Guan A, Xue J, Li B, Huang Z, et al. Footprints: Stamping hallmarks of lung cancer with patient-derived models, from molecular mechanisms to clinical translation. Front Bioeng Biotechnol [Internet]. 21 févr 2023 [cité 26 nov 2024];11. Disponible sur: https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2023.1132940/full

11. Mogi A, Kuwano H. TP53 Mutations in Nonsmall Cell Lung Cancer. J Biomed Biotechnol. 2011;2011:583929.

12. Shi R, Li M, Raghavan V, Tam S, Cabanero M, Pham NA, et al. Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma. Clinical Cancer Research. 3 déc 2018;24(23):5990-6000.

13. Wohlhieter CA, Richards AL, Uddin F, Hulton CH, Quintanal-Villalonga À, Martin A, et al. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Reports [Internet]. 1 déc 2020 [cité 26 nov 2024];33(9). Disponible sur: https://www.cell.com/cell-reports/abstract/S2211-1247(20)31433-9

14. Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, et al. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell. 10 août 2020;38(2):229-246.e13.
15. Frankell AM, Dietzen M, Al Bakir M, Lim EL, Karasaki T, Ward S, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. avr 2023;616(7957):525-33.

16. Baldacci S, Blons H, Mascaux C, Leroy K. Oncogenèse pulmonaire : de l'altération moléculaire au cancer. Revue des Maladies Respiratoires Actualités. 1 oct 2024;16(2, Supplement 1):2S10-8.

17. Tan AC, Tan DSW. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 20 févr 2022;40(6):611-25.

18. Arriola E, Trigo JM, Sánchez-Gastaldo A, Navarro A, Perez C, Crama L, et al. Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database Analysis. JTO Clin Res Rep. 10 déc 2021;3(1):100266.

19. Berghmans T, Brandão M. Les maladies oligométastatiques : état actuel et perspectives dans les cancers bronchiques non à petites cellules. Revue des Maladies Respiratoires. 1 oct 2023;40(8):684-91.

20. Kang H, Do W, Ahn YC, Chie EK, Rim CH. A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation. European Journal of Cancer. nov 2024;212:115043.

21. Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, Brunelli M, et al. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res. 29 déc 2011;30(1):115.

22. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacology & Therapeutics. 1 janv 1994;64(3):529-64.

23. Leach DR, Krummel MF, Allison JP. Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science. 22 mars 1996;271(5256):1734-6.

24. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 17 sept 2002;99(19):12293-7.

25. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 9 avr 2016;387(10027):1540-50.

26. Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet. 4 mai 2019;393(10183):1819-30.

27. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New England Journal of Medicine. 22 nov 2018;379(21):2040-51.

28. Kim H, Kim D, Kim M, Lee Y, Ahn HK, Cho JH, et al. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of
immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11). Cancer. 15 févr 2022;128(4):778-87.

29. Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. JCO. 10 avr 2023;41(11):1999-2006.

30. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal of Medicine. 11 janv 2018;378(2):113-25.

31. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine. 2 janv 2020;382(1):41-50.

32. Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naïve advanced ALK-positive non-small-cell lung cancer in the ALEX study. Annals of Oncology. 1 août 2020;31(8):1056-64.

33. Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol. 10 oct 2024;42(29):3400-9.

34. Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 26 mai 2022;386(21):1973-85.

35. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 29 oct 2020;383(18):1711-23.

36. Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine. 10 avr 2024;390(14):1265-76.

37. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. New England Journal of Medicine. 13 déc 2018;379(24):2342-50.

38. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. The Lancet Oncology. 1 déc 2016;17(12):1672-82.

39. Iyengar P, All S, Berry MF, Boike TP, Bradfield L, Dingemans AMC, et al. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline. Practical Radiation Oncology. 1 sept 2023;13(5):393-412.

40. Guo T, Ni J, Yang X, Li Y, Li Y, Zou L, et al. Pattern of Recurrence Analysis in Metastatic EGFR-Mutant NSCLC Treated with Osimertinib: Implications for Consolidative Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics. 1 mai 2020;107(1):62-71.
41. Wang XS, Bai YF, Verma V, Yu RL, Tian W, Ao R, et al. Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. JNCI: Journal of the National Cancer Institute. 1 juin 2023;115(6):742-8.

42. Soares M, Toffart AC, Timsit JF, Burghi G, Irrazábal C, Pattison N, et al. Intensive care in patients with lung cancer: a multinational study. Annals of Oncology. 1 sept 2014;25(9):1829-35.

43. Cantón-Bulnes ML, Jiménez-Sánchez M, Alcántara-Carmona S, Gimeno-Costa R, Berezo-García JÁ, Beato C, et al. Determinants of mortality in cancer patients with unscheduled admission to the Intensive Care Unit: A prospective multicenter study. Med Intensiva (Engl Ed). déc 2022;46(12):669-79.

44. Martos-Benítez FD, Soto-García A, Gutiérrez-Noyola A. Clinical characteristics and outcomes of cancer patients requiring intensive care unit admission: a prospective study. J Cancer Res Clin Oncol. 1 avr 2018;144(4):717-23.

45. Liu W, Zhou D, Zhang L, Huang M, Quan R, Xia R, et al. Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China. J Cancer Res Clin Oncol. 20 avr 2024;150(4):205.

46. Andréjak C, Terzi N, Thielen S, Bergot E, Zalcman G, Charbonneau P, et al. Admission of advanced lung cancer patients to intensive care unit: A retrospective study of 76 patients. BMC Cancer. déc 2011;11(1):159.

47. Soares M, Salluh JIF, Torres VBL, Leal JVR, Spector N. Short- and Long-term Outcomes of Critically Ill Patients With Cancer and Prolonged ICU Length of Stay. CHEST. 1 sept 2008;134(3):520-6.

48. Reichner CA, Thompson JA, O'Brien S, Kuru T, Anderson ED. Outcome and Code Status of Lung Cancer Patients Admitted to the Medical ICU. CHEST. 1 sept 2006;130(3):719-23.

49. Toffart AC, Pizarro CA, Schwebel C, Sakhri L, Minet C, Duruisseaux M, et al. Selection criteria for intensive care unit referral of lung cancer patients: a pilot study. Eur Respir J. févr 2015;45(2):491-500.

50. Toffart AC, Meert AP, Wallet F, Gibelin A, Guisset O, Gonzalez F, et al. ICU admission for solid cancer patients treated with immune checkpoint inhibitors. Ann Intensive Care. 18 avr 2023;13:29.

51. Meert AP, Toffart AC, Picard M, Jaubert P, Gibelin A, Bauer P, et al. When targeted therapy for cancer leads to ICU admission. RETRO-TARGETICU multicentric study. Bulletin du Cancer. sept 2022;109(9):916-24.

52. Gorham J, Ameye L, Paesmans M, Berghmans T, Sculier JP, Meert AP. Cancer bronchique : le pronostic en soins intensifs dépendrait surtout de la complication. Revue des Maladies Respiratoires. mars 2019;36(3):333-41.

53. Song JH, Kim S, Lee HW, Lee YJ, Kim M jung, Park JS, et al. Effect of intensivist involvement on clinical outcomes in patients with advanced lung cancer admitted to the intensive care unit. PLoS One. 13 févr 2019;14(2):e0210951.

54. Vigneron C, Charpentier J, Wislez M, Mira JP, Lefebvre A, Fournel L, et al. Short-term
and Long-term Outcomes of Patients With Lung Cancer and Life-Threatening Complications. Chest. 1 oct 2021;160(4):1560-4.

55. Shen CI, Yang SY, Chiu HY, Chen WC, Yu WK, Yang KY. Prognostic factors for advanced lung cancer patients with do-not-intubate order in intensive care unit: a retrospective study. BMC Pulm Med. 24 juin 2022;22(1):245.

56. Özpınar ŞN, Gürün Kaya A, Öz M, Erol S, Arslan F, Çiledağ A, et al. [Prognosis of lung cancer patients followed in the intensive care unit: A cross-sectional study]. Tuberk Toraks. juin 2023;71(2):138-47.

57. Chatelain E, Simon M, Hernu R, Argaud L, Cour M. Factors associated with short- and long-term outcomes in lung cancer patients requiring unplanned invasive mechanical ventilation. Medicina Intensiva. 1 janv 2024;48(1):37-45.

58. Zerbib Y, Rabbat A, Fartoukh M, Bigé N, Andréjak C, Mayaux J, et al. Urgent Chemotherapy for Life-Threatening Complications Related to Solid Neoplasms. Critical Care Medicine. juill 2017;45(7):e640-8.

59. Boulet N, Boussere A, Mezzarobba M, Sofonea MT, Payen D, Lipman J, et al. Intensive Care Unit activity in France from the national database between 2013 and 2019: More critically ill patients, shorter stay and lower mortality rate. Anaesthesia Critical Care & Pain Medicine. 1 oct 2023;42(5):101228.

60. Zhong S, Yang H, Zhao Z. Mortality rate analysis of patients on invasive mechanical ventilation in the intensive care unit on day 28. Biomedical Reports. 1 oct 2024;21(4):1-8.

61. Abate SM, Basu B, Jemal B, Ahmed S, Mantefardo B, Taye T. Pattern of disease and determinants of mortality among ICU patients on mechanical ventilator in Sub-Saharan Africa: a multilevel analysis. Critical Care. 24 janv 2023;27(1):37.

62. Lee IH, Yang CY, Shih JY, Yu CJ. Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation. Biomedicines. 8 oct 2021;9(10):1416.

63. Shen R, Martin A, Ni A, Hellmann M, Arbour KC, Jordan E, et al. Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. JCO Precis Oncol. mars 2019;(3):1-9.

64. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, et al. Survival in neutropenic patients with severe sepsis or septic shock*: Critical Care Medicine. janv 2012;40(1):43-9.

65. Yesiloz A, Sanchez S, Mesrar H, Chrusciel J, Dacunka M, Raoul F, et al. [Patients hospitalized in the ICU for acute coronary syndrome from 2012 to 2021: A single-center retrospective study]. Ann Cardiol Angeiol (Paris). nov 2024;73(5):101799.

66. Kim JS, Shin J, Kim NH, Lee SY, Yoo SH, Keam B, et al. Use of high-flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life. Cancer Medicine. 2023;12(13):14612-22.

67. Grand-Clément J, Chan CW, Goyal V, Escobar G. Robustness of Proactive Intensive Care Unit Transfer Policies. Operations Research. sept 2023;71(5):1653-88.
<figure><img src="image_15.png" /></figure>
# Etude des facteurs pronostiques de mortalité en soins intensifs et réanimation des cancers broncho-pulmonaires non à petites cellules de stade avancé au CHU d'Amiens

**Introduction** : Le cancer broncho-pulmonaire non à petites cellules (CBNPC) de stade avancé est fréquent et son pronostic s'est récemment amélioré grâce à l'utilisation de l'immunothérapie et des thérapies ciblées. L'admission en réanimation de ces patients soulève la question de la balance bénéfices-risques. L'étude MUSIC, menée au CHU d'Amiens, vise à identifier les profils de patients pouvant tirer profit d'une prise en charge en soins intensifs.

**Matériel et méthodes** : Étude rétrospective, observationnelle, monocentrique incluant 101 patients atteints de CBNPC de stade IIIA à IVB admis en unités de soins critiques entre 2018 et 2023. Les données cliniques, oncologiques et de réanimation ont été analysées. Le critère de jugement principal était la mortalité intra-USI.

**Résultats** : La mortalité intra-USI est de 31,7 %. Deux facteurs indépendants protecteurs de cette mortalité ont été identifiés : un performance status (PS) de 0-1 et un stade tumoral III ou oligométastatique. En revanche, la ventilation mécanique était un facteur de mauvais pronostic. La médiane de survie des patients survivants était proche de celle des CBNPC traités hors réanimation, et plus d'un tiers des patients ont pu reprendre un traitement oncologique par la suite.

**Discussion** : Nos résultats confirment que certains patients atteints de CBNPC avancés peuvent bénéficier d'une admission en réanimation, à condition d'une sélection rigoureuse. La réanimation ne semble pas compromettre leur avenir thérapeutique.

**Conclusion** : L'identification de patients éligibles à une prise en charge intensive en cas de dégradation aigue est essentielle pour optimiser le pronostic sans induire de soins disproportionnés. Notre étude apporte des arguments pour faciliter cette décision thérapeutique.

**Mots-clés** : "Tumeurs pulmonaires", "Carcinome pulmonaire non à petites cellules", "Unités de soins intensifs", "Études rétrospectives", "Facteurs de risque"

# Study of prognostic factors of mortality in intensive care and resuscitation of advanced non-small cell bronchopulmonary cancers at Amiens University Hospital.

**Introduction** : Advanced non-small cell lung cancer (NSCLC) is common, and its prognosis has recently improved thanks to immunotherapy and targeted therapies. The admission of these patients of these patients raises the question of benefit-risk. The MUSIC study, conducted at CHU d'Amiens, aims to identify patient profiles that could benefit from intensive care management.

**Material and methods** : Retrospective, observational, monocentric study including 101 patients with stage IIIA to IVB admitted to critical care units between 2018 and 2023. Clinical, oncological and resuscitation data were analyzed. The primary endpoint was intra-ICU mortality.

**Results** : Intra-ICU mortality was 31.7%. Two independent protective factors were identified: a performance status (PS) of 0-1 and tumor stage III or oligometastatic. On the other hand, mechanical ventilation was a poor prognostic factor. The median survival of surviving patients was close to that of NSCLC patients treated outside the ICU, and more than a third of patients were able to resume oncological treatment afterwards.

**Discussion** : Our results confirm that some patients with advanced NSCLC may benefit from admission to the intensive care unit, provided rigorous selection. Intensive care does not appear to compromise their therapeutic future.

**Conclusion** : Identifying patients eligible for intensive management in the event of acute deterioration is essential to optimize prognosis without inducing disproportionate care. Our study provides arguments to facilitate this therapeutic decision.

**Mots-clés** : "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Intensive Care Units", "Retrospective Studies", "Risk Factors".